Single Cell Acute Leukemia Analysis

NCT ID: NCT06906978

Last Updated: 2025-04-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-31
• Study Completion Date: 2029-07-31

Brief Summary

Numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular. As a preliminary to this study, the investigators hypothesized the co-expression of these genes in the same cell as a major factor in relapse. This hypothesis was supported in vitro by the study of the evolution of these co-expressions after incubation with chemotherapy drugs. The current study aims to verify this hypothesis by studying the expression of these genes in single-cell samples from relapsed acute myeloid leukemia patients.

Conditions

Acute Myeloid Leucemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Patient with acute myeloid leukemia

Adult patient with acute myeloid for whom an additionnal 20 mL of blood will be collected.

Group Type: OTHER

blood sampling

Intervention Type: PROCEDURE

Patients will be seen in hospital as part of their routine care, during which a blood test will be prescribed. On this occasion, an additional 20 mlof blood will be collected for research purposes.

Interventions

blood sampling

Patients will be seen in hospital as part of their routine care, during which a blood test will be prescribed. On this occasion, an additional 20 mlof blood will be collected for research purposes.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Adult patient
• Patient who has received information about the study and has not expressed opposition,
• Patients who are beneficiaries of a social security plan,
• Patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse.

Exclusion Criteria

• Persons who do not understand the French language if there is no translator available to translate for them.
• Absence of circulating blastosis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Régis Costello, Professor

Role: PRINCIPAL_INVESTIGATOR

Assitance Public - Hôpitaux de Marseille

Central Contacts

clement PIERRE, PhD

Role: CONTACT

clement.pierre@ap-hm.fr

+33491435796

Other Identifiers

2025-A00734-45.

Identifier Type: OTHER

Identifier Source: secondary_id

RCAPHM25_0039

Identifier Type: -

Identifier Source: org_study_id